Adverum Biotechnologies, Inc.
ADVM
$4.22
-$0.01-0.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -183.87M | -165.18M | -145.31M | -113.44M | -119.20M |
| Total Depreciation and Amortization | 2.92M | 3.34M | 3.65M | 3.85M | 4.47M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 31.29M | 36.61M | 38.67M | 26.32M | 33.21M |
| Change in Net Operating Assets | 18.75M | 13.24M | 10.53M | -2.27M | -6.82M |
| Cash from Operations | -130.91M | -111.99M | -92.46M | -85.54M | -88.33M |
| Capital Expenditure | -622.00K | -518.00K | -388.00K | -519.00K | -793.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 46.27M | 11.94M | -41.50M | -47.06M | -15.24M |
| Cash from Investing | 45.65M | 11.42M | -41.89M | -47.58M | -16.04M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 359.00K | 239.00K | 120.12M | 120.12M | 120.12M |
| Repurchase of Common Stock | -- | -116.00K | -116.00K | -116.00K | -116.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -76.00K | -182.00K |
| Cash from Financing | 359.00K | 123.00K | 120.00M | 119.93M | 119.83M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -84.90M | -100.45M | -14.35M | -13.19M | 15.46M |